SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Antibody-Drug Conjugates in Perioperative Treatment of Muscle-Invasive Bladder Cancer: Expert Perspectives

This article discusses the emerging role of antibody-drug conjugates (ADCs) in the perioperative treatment of muscle-invasive bladder cancer

Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference

Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre

Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial

Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic

Antibody-ligand motif optimization enables multitarget switchable CAR-T therapy against solid tumors

This article presents a research study on optimizing a multitarget switchable CAR-T (sCAR-T) strategy to overcome antigenic heterogeneity an

FDA-approved drug may finally help immunotherapy defeat rare liver cancer

AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers

Researchers developed an AI-driven framework for discovering CAR T cell therapy targets by integrating single-cell RNA sequencing data from